Fleroxacin Injection

This product is a fluoroquinolone antibacterial drug. It has strong antibacterial effects on Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus, Salmonella typhi, Salmonella paratyphi, Shigella, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter, Serratia marcescens, Pseudomonas aeruginosa, Neisseria meningitidis, Haemophilus influenzae, Moracata, Legionella pneumophila, Neisseria gonorrhoeae, etc. It also has moderate antibacterial effects on Gram-positive cocci such as Staphylococcus and hemolytic Streptococcus. In recent years, bacterial resistance to fluoroquinolones has increased significantly, especially in Escherichia coli, with a resistance rate of more than 50%. The mechanism of action of this product is to inhibit the bacterial DNA gyrase and thus kill bacteria.

Fleroxacin: 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid. [Molecular formula] C17H18F3N3O3 [Molecular weight] 369.34

This product is a yellow-green clear liquid.

It can be used for the following respiratory infections caused by bacteria that are sensitive to this product: acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, etc.; urogenital system infections such as cystitis, pyelonephritis, prostatitis, epididymitis, gonorrhea Neisseria urethritis, etc.; digestive system infections such as typhoid Salmonella infection, bacillary dysentery, etc.; skin and soft tissue infections, bone infections, abdominal infections and pelvic infections, etc.

Inject slowly by intravenous drip in a dark place, 0.2-0.4 g at a time, once a day, diluted in 250-500 ml of 5% glucose injection.

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea and vomiting, and loss of appetite. 2. Central nervous system reactions may include dizziness, headache, excitement, drowsiness or insomnia. 3. Allergic reactions include rash and skin itching, and occasionally exudative erythema multiforme and angioneurotic edema. A small number of patients have photosensitivity reactions. 4. A small number of patients may experience increased blood aminotransferase and blood urea nitrogen and decreased peripheral white blood cell counts, which are mostly mild and transient. 5. Occasionally, the following may occur: (1) Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, and tremors. (2) Interstitial nephritis manifestations such as hematuria, fever, and rash. (3) Crystalluria, which is more common when high doses are used.

1. Those who are allergic to this product or quinolone drugs are prohibited from using this product. 2. Pregnant women, lactating women and patients under 18 years old are prohibited from using this product.

Precautions for children: Fluoroquinolones can cause permanent damage to the cartilage of weight-bearing joints in dogs, leading to lameness, and can also cause arthritis in several other underage animals, so they are contraindicated in patients under 18 years of age. In infections caused by multidrug-resistant bacteria, when the bacteria are only sensitive to fluoroquinolones, this product can only be used in children after weighing the pros and cons. Precautions for pregnancy and lactation: Fluoroquinolones can pass through the blood-placental barrier and can be secreted into breast milk, and their concentration is close to the blood drug concentration, so they are contraindicated for pregnant and lactating women. Precautions for the elderly: Elderly patients have reduced renal function, and the dosage should be reduced as appropriate.

1. The aluminum and magnesium contained in didanosine (DDI) preparations can chelate with fluoroquinolones and should not be used together. 2. Urine alkalinizers can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 3. Probenecid can delay the excretion of this product, increase the blood concentration of this product and produce toxicity.

Keep away from light, tightly closed and in a cool place.

2ml:0.2g

Jilin Jian Yisheng Pharmaceutical Co., Ltd.

• Founded in:

  1997-06-11

• Address:

  No. 17-20, Wenhua East Road, Ji'an City, Jilin Province

• Tax NO.:

  91220501126870028U

• Registered Funds:

  330.9516 million yuan

• Website:

  Log in to view

• Email:

  Log in to view